Development of drug resistance is a major obstacle against successful chemotherapy of many currently-used anticancer drugs in clinics as the resistance often leads to recurrence of the disease. CIL-102, a plant (Zanthoxylum simulans) derived alkaloid is highly potent against multi-drug resistant cancer. We have identified the cellular target of CIL-102 and unraveled the mechanisms of action of the drug in breast cancer cells. Our findings suggest that CIL-102 may be considered as a potential lead compound in anticancer therapy, especially against chemo-resistant cancer.
 |
|||||
| KK Gireesh, Rashid A, Chakraborty S, Panda D, and Manna T* Biochemical Pharmacology (in Press) | |||||
| CIL-102 binds to microtubule protein tubulin at a novel site | |||||
|
|||||
| CIL-102 induces severe phenotypes like, monopolarity and multinucleation in breast cancer cells | |||||
 |
|||||
| CIL-102 kills cancer cells via p53-p21 pathway | |||||
|
|||||
